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Suppressor T cells: Rebirth, function and homeostasis
Ethan M. Shevach
A minor subpopulation of CD4+ T cells that co-express
the cell-surface molecule CD25 has emerged as the
major population of T cells responsible for
downregulation of the immune response and
prevention of autoimmunity. 
Address: Laboratory of Immunology, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland, USA.
E-mail: ems1@box-e.nih.gov
Current Biology 2000, 10:R572–R575
0960-9822/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
The late R.K. Gershon is usually credited with the con-
ceptual discovery of suppressor T cells as that population
of T cells specifically equipped to inhibit immune
responses, including both antibody production by B lym-
phocytes and the activation of other T cells such as cyto-
toxic T cells. It was believed during much of the 1970s
and early 1980s that suppressor T cells mediated their bio-
logical functions by producing antigen-specific soluble
factors that bore determinants encoded by a specific
region (termed I–J) of the murine major histocompatibility
complex (MHC) and/or determinants encoded by
immunoglobulin genes. The cloning of the genes encod-
ing the T-cell receptor in the mid-1980s clearly demon-
strated that the genes encoding the T-cell receptor were
not identical to the immunoglobulin genes and other mol-
ecular studies failed to identify an I–J gene within the
MHC. The field of T-cell-mediated suppression was left
in disarray and most of the investigators who were active
participants rapidly abandoned what was regarded as a
sinking ship. Over the past 5–10 years, suppressor T cells
have experienced somewhat of a revival. Here, I will
review recent experimental evidence that has led us to
regard suppressor T cells again as members of a separate
lineage of cells that is responsible for downregulation of
the immune response. 
Rebirth 
The experiments that reaffirm the existence and support
the importance of suppressor T cells have come from
studies involving the induction of organ-specific autoim-
munity by manipulation of lymphocyte homeostasis. Two
series of studies initiated more than 25 years ago formed
the basis for the concept that depletion of regulatory
T cells leads to the induction of autoimmunity. Removal
of thymuses from mice on the third day of life was
observed to lead to the development of a wide spectrum
of organ-specific autoimmune disease [1] (Figure 1). The
effector T cells responsible for the induction of disease
were shown to express the CD4 coreceptor. Given that
mice that were thymectomized on day 7 of life did not
develop autoimmune disease, it was postulated that a pop-
ulation of regulatory T cells developed slightly later in
ontogeny than the autoimmune effectors and that thymec-
tomy on day 3 prevented the emigration of these regula-
tory cells to the peripheral lymphoid tissues. Indeed,
autoimmune disease could be prevented by reconstitution
of T cells in these mice either with a thymus transplant or
by the injection of a suspension of normal CD4+ T cells
from adult mice before day 14 of life.
One logical extension of the hypothesis put forth to
explain this model is that autoreactive effectors and sup-
pressors must co-exist in the normal adult animal and that
removal of the suppressor population leads to the develop-
ment of autoimmune disease. Strong support for this
concept was derived from studies in the mid-1970s that
demonstrated that thymectomy of adult rats (Figure 1)
that normally were resistant to the development of
autoimmunity, followed by fractional doses of sublethal
irradiation (to deplete peripheral lymphoid cells), resulted
in the development of autoimmune thyroiditis [2]. Most
importantly, the active role for regulatory T cells in this
model was demonstrated by preventing the development
of autoimmunity by reconstitution of the thymectomized,
irradiated rats with lymphoid cells from normal donors
after the final dose of irradiation. 
Although these early experiments supported the existence
of a population of unique regulatory cells, further progress
was slow as it proved difficult to distinguish regulatory
T cells from effector cells on the basis of the expression of
unique membrane markers. Sakaguchi et al. [1] were the
first to suggest that regulatory T cells could be separated
from effectors on the basis of the relative expression of the
Lyt-1 (CD5) antigen. The Lyt-1 antigen in the mouse is
expressed on all T cells, however, and the suppressor cells
were contained in the large (80%) subset of cells that
express high levels of the Lyt-1 antigen. In the early 1990s,
Mason’s group was able to differentiate suppressors and
effectors in the rat model on the basis of the differential
expression of the RB isoform of the CD45 antigen. Subse-
quently, Powrie and Mason [3] extended this approach to
the mouse and demonstrated that severe inflammatory
bowel disease could be induced in immunodeficient mice
that were injected with CD4+CD45RBhigh T cells
(Figure 1), while mice that received CD4+CD45RBlow
T cells or a mixture of the two subsets never developed
intestinal lesions [3]. 
A major advance in the field was the demonstration by
Sakaguchi et al. [4] in the mouse model that suppressor
cells were exclusively present in the minor population
(8–10%) of CD4+ T cells that co-express CD25, the inter-
leukin-2 (IL-2) receptor α chain. Thus, transfer of CD4+
T cells from normal adult mice that had been depleted
in vitro of the CD4+CD25+ subset to immunodeficient
recipients led to the development of a spectrum of autoim-
mune disease that resembled that seen after thymectomy
at day 3 (Figure 1). Transfer of the CD4+CD25+ T cells
within 10 days of transfer of the CD4+CD25– cells com-
pletely prevented the development of disease. Although
CD45RBlow cells do not all express CD25, Read et al. [5]
have recently demonstrated that, in the CD45RBlow popu-
lation, it is only the CD4+CD25+ subset that is responsible
for the prevention of inflammatory bowel disease when co-
transferred with CD45RBhigh cells. 
Function
One of the major problems in studying the mechanism of
suppressor T-cell function in vivo in autoimmunity
models is that the assay systems are both indirect and
complex as well as requiring weeks to months for the
assessment of disease activity. In vitro model systems that
potentially mimic the function of the suppressor cells
in vivo have offered considerable insight. CD4+CD25+
cells appear to be anergic when stimulated via their T-cell
receptor or with IL-2 alone, yet they proliferate vigorously
when stimulated with the combination of anti-CD3 anti-
bodies and IL-2 [6]. These cells potently suppress the
responses of CD4+CD25– T cells in co-culture experi-
ments. The properties of this cytokine-independent, cell
contact-dependent suppression are presented in Table 1.
The role of suppressor cytokines in mediating the function
of the CD4+CD25+ cells in vivo is much more controversial.
The protective effect of the CD45RBlow suppressor popula-
tion in the mouse inflammatory bowel disease model can be
reversed by antibodies against the IL-10 receptor or against
transforming growth factor β (TGFβ), while the protective
effect of the rat CD45RBlow cells in the thyroiditis model
can be reversed by anti-IL-4 and anti-TGFβ antibodies [3].
In contrast, the suppressive effects of the CD4+CD25+
T cells on the development of autoimmune gastritis cannot
be reversed with antibodies against IL-4, IL-10 or TGFβ,
and CD4+CD25+ T cells from IL-4- and IL-10-deficient
mice are also fully competent at mediating suppression [6].
It is possible that the CD4+CD25+ population, upon appro-
priate activation in vivo, differentiates into subsets of sup-
pressor effectors, some of which mediate suppression by a
cell-contact-dependent mechanism, while others mediate
suppression by secreting suppressor cytokines.
What is the cellular target for the suppressive activity of
the CD4+CD25+ T cells? If their activity is mediated by
suppressor cytokines that function as deactivators of
antigen-presenting cell function, then these cells are the
logical target. Inhibition of antigen-presenting cell func-
tion would prevent the activation of the autoreactive
effector population. A cell-contact-dependent mechanism
of suppression could also target the antigen-presenting
cell, but recent studies from my laboratory (reviewed in
[6]) do not support this view and we favor the possibility
that the target of the CD4+CD25+ suppressor is the
responder CD4+CD25– T-cell population [7]. 
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Table 1
Properties of CD4+CD25+ T-cell-mediated suppression.
Requires activation of CD4+CD25+ T cell
Requires cell–cell contact
Independent of IL-4, IL-10, TGFβ
Overcome by IL-2 or anti-CD28 antibodies
Accompanied by cell-cycle arrest
Mediated by inhibition of IL-2 production
Figure 1
Various types of organ-specific autoimmune
disease — such as gastritis, orchitis,
oophoritis, thyroiditis, diabetes, inflammatory
bowel disease — can be induced by
depletion of regulatory T cells in vivo or in
vitro. See text for details of these models.
Both mouse and rat regulatory and effector
cells can be distinguished by expression of
the CD45RB isoforms.
In vitro depletionAdult thymectomyThymectomy
at day 3
Irradiation
CD45RBlow
CD45RBhigh
In vitro depletion
CD4+CD25+
CD4+CD25–
Rat
CD25–
Mouse
Organ-specific autoimmunity
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CD4+CD25+ T cells develop in the thymus with CD25
expression first being detected when CD4+CD8+ thymo-
cytes differentiate into single-positive CD4+ or CD8+
T cells [8]. Around 5% of CD4+CD8– thymocytes and less
than 0.3% of CD4–CD8+ thymocytes express the CD25
molecule. What is the physiological ligand recognized by
the T-cell receptor of the CD4+CD25+ T cells during thy-
mocyte development and what is the ligand responsible
for their activation in the periphery? My group has
hypothesized that CD4+CD25+ T cells are generated in
the thymus during the process of negative selection.
These cells bear T-cell receptors that are specific for self-
antigens with intermediate affinity such that they are not
deleted, yet not allowed to pass through to the periphery.
The cells undergo a process we have termed ‘altered neg-
ative selection’, which results in a permanent change in
their T-cell receptor signal transduction process, so that
they leave the thymus in a partially incapacitated state and
are precommitted to function as suppressor cells when
they encounter their target antigen in the periphery [6].
The possibility that the CD4+CD25+ T cells recognize
organ-specific antigens was originally proposed because
the development of orchitis after thymectomy at day 3
could be inhibited by regulatory T cells from males, but
not from females or orchiectomized males [1]. CD45RBlow
T cells from the peripheral lymphoid tissues of normal
rats, but not rats lacking thyroid glands, are able to sup-
press thyroiditis induced by transfer of CD4+CD45RBhigh
T cells, while regulatory T cells from the thymus of athry-
oid animals are fully competent suppressors [9]. This
result suggests that the development of the regulatory
T cells in the thymus is normal, but that their maintenance
or survival in the periphery requires the presence of the
target antigen. Although it is not yet known whether the
antigen responsible for their development in the thymus is
related to their target antigen in the periphery, this possi-
bility may indeed be the case because many supposedly
‘organ-specific’ antigens are also expressed in the thymus. 
In addition to their specific target antigen, the other factor
required for survival of the CD4+CD25+ T cells is IL-2,
because this population of cells is absent in IL-2-deficient
mice [8]. As the CD4+CD25+ T cells are incapable of pro-
ducing IL-2, it is likely that they respond to low levels of
IL-2 constitutively produced by CD25– T cells. CD28-
deficient mice have only half the number of CD4+CD25+
cells — consistent with the view that the interaction of
CD28 with its ligands CD80/CD86 is the major costimula-
tory signal needed for IL-2 production. One might there-
fore predict that blockade of the interaction of CD28 with
its ligands might, in certain circumstances, lead to the
development of autoimmunity. Salomon et al. [10] have
recently reported that only 5–6% of CD4+ T cells in dia-
betes-prone non-obese diabetic (NOD) mice express
CD25. When NOD mice are rendered deficient in either
CD28 or in CD80/CD86, only 1–1.5% of the CD4+ T cells
express CD25. Both of the deficient strains have an
increased severity of autoimmune diabetes, which can be
prevented by reconstitution with CD4+CD25+ T cells
from NOD donors. Thus, the exacerbation of diabetes in
NOD mice deficient in CD80/CD86 or CD28 appears to
be secondary to a deficiency in regulatory T cells. 
A second intriguing feature of the CD4+CD25+ T-cell
population is that it is the only cell population in the
normal mouse that appears to constitutively express cyto-
toxic T lymphocyte associated protein 4 (CTLA-4, also
known as CD152) [5,10,11]. While CTLA-4 is structurally
related to CD28 and interacts with the same ligands
(CD80/CD86), it is widely accepted that triggering of
CTLA-4 on activated T cells results in downregulation of
T-cell activation rather than in costimulation. As expres-
sion of CTLA-4 is normally upregulated during the
process of T-cell activation, it is possible that expression
of CTLA-4 on the CD4+CD25+ T cells is merely related
to their partially activated phenotype which is induced
during development of the CD4+CD25+ cells in the
thymus. Alternatively, CTLA-4 may play a role in the
process of T-cell suppression. 
Two observations support the latter possibility. First, sup-
pression of inflammatory bowel disease mediated by
Figure 2
Model for the activation of the CD4+CD25+ T cell by the interaction of
CD80/CD86 with CTLA-4. The resulting suppression might be
mediated by TGFβ or by a cell-associated suppressor molecule.
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CD25+CD45RBlow T cells was reversed by treatment of
the animals with anti-CTLA-4 antibodies [5]. One expla-
nation for this result is that the production of the critical
suppressive cytokine needed for protection from inflam-
matory bowel disease, TGFβ, was blocked by the anti-
CTLA-4 antibody treatment, because CTLA-4 triggering
has been shown to result in the production of TGFβ
(Figure 2). Second, addition of anti-CTLA-4 antibody to
co-cultures of mitogen-stimulated CD4+CD25+ and
CD4+CD25– T cells resulted in abrogation of the suppres-
sive activity of the CD4+CD25+ population [11]. TGFβ
has been ruled out of playing any role in the suppression of
lymphocyte proliferation in vitro in this particular  model,
but it is possible that ligation of CTLA-4 plays a role in
costimulation of suppressor effector function (Figure 2).
One other study [12] that supports the role of CTLA-4 in
the induction of suppression is that when immunodefi-
cient mice are reconstituted with bone marrow containing
CTLA-4-deficient T cells, they develop autoimmunity,
whereas when they are reconstituted with a mixture of
CTLA-4-deficient and normal cells, they show no signs of
disease. Thus, the autoimmunity observed in CTLA-4-
deficient mice is not due to a T-cell-autonomous defect
and triggering of CTLA-4 on normal T cells leads to the
induction of expression of a membrane molecule or
secreted cytokine that downregulates the autoreactivity of
the CTLA-4-deficient T cells. 
Taken together, these papers suggest that CTLA-4 may
have a critical role in some of the steps required for induc-
tion of regulatory T cell function. If further studies
confirm that the interaction of CD80/CD86 with CTLA-4
is required for activation of regulatory T cells, these
results will have profound implications for ongoing clinical
trials investigating the use of anti-CD80/CD86 reagents
for the therapy of autoimmune disease. Blockade of regu-
latory T cell functions may result in harmful rather than
beneficial effects. 
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